{
    "clinical_study": {
        "@rank": "8105", 
        "arm_group": [
            {
                "arm_group_label": "Inflaminat", 
                "arm_group_type": "Active Comparator", 
                "description": "Inflaminat 500 mg tablet by mouth three times a day"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo 500 mg tablet by mouth three times a day"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the anti-atherosclerotic effect of long-term\n      anti-inflammatory therapy (Inflaminat) in asymptomatic participants with subclinical\n      atherosclerosis of carotid arteries."
        }, 
        "brief_title": "Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Carotid Atherosclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Carotid Artery Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Men aged 40 to 70 years\n\n          -  Subclinical carotid atherosclerosis detected by B-mode ultrasound (increased\n             intima-media thickness 1000-2000 mcm)\n\n          -  Arterial normotension or mild arterial hypertension (systolic blood pressure <160 mm\n             Hg, diastolic blood pressure <90 mm Hg)\n\n          -  Absence of chronic diseases demanding permanent drug administration (more than 2\n             month per year)\n\n        Exclusion Criteria:\n\n          -  Personal history of stroke or transient ischemic attacks\n\n          -  Chronic diseases demanding drug administration more than during 2 month per year\n\n          -  Individual intolerance of Inflaminat or appearance of side effects"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01743404", 
            "org_study_id": "IAR-INFL"
        }, 
        "intervention": [
            {
                "arm_group_label": "Inflaminat", 
                "intervention_name": "Inflaminat", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Sugar pill", 
                "description": "Sugar pill manufactured to mimic Inflaminat 500 mg tablet", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "atherosclerosis", 
            "inflammation", 
            "intima-media thickness"
        ], 
        "lastchanged_date": "December 4, 2012", 
        "location": {
            "contact": {
                "email": "igor.sobenin@gmail.com", 
                "last_name": "Igor Sobenin, MD", 
                "phone": "+79263590050"
            }, 
            "contact_backup": {
                "email": "katrincorde@gmail.com", 
                "last_name": "Ekaterina Chernova", 
                "phone": "+79166647123"
            }, 
            "facility": {
                "address": {
                    "city": "Moscow", 
                    "country": "Russian Federation"
                }, 
                "name": "Institute for Atherosclerosis Research"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_arms": "2", 
        "official_title": "Double-blinded Placebo-controlled Multicenter Study of Anti-atherosclerotic Activity of Inflaminat in Asymptomatic Participants With Subclinical Atherosclerosis", 
        "overall_contact": {
            "email": "igor.sobenin@gmail.com", 
            "last_name": "Igor Sobenin, MD", 
            "phone": "+79263590050"
        }, 
        "overall_contact_backup": {
            "email": "katrincorde@gmail.com", 
            "last_name": "Ekaterina Chernova", 
            "phone": "+79166647123"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Variation of intima-media thickness of common carotid arteries", 
            "measure": "B-mode ultrasound of carotid arteries", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01743404"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Change of the ability of serum to induce cholesterol accumulation in cultured cells", 
            "measure": "Measure of serum atherogenicity", 
            "safety_issue": "Yes", 
            "time_frame": "up to 2 years"
        }, 
        "source": "Institute for Atherosclerosis Research, Russia", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute for Atherosclerosis Research, Russia", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2007", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}